E6 and E7 fusion immunoglobulin from human papilloma virus 16 induces dendritic cell maturation and antigen specific activation of T helper 1 response

Biotechnology Letters

Volumn 33, Issue 4, 2011, Pages 663-671

  Kim, Sang Hoon ^a   Hur, Yu Jin ^a   Lee, Suk Jun ^a   Kim, Sang Joon ^b   Park, Chung Gyu ^c   Oh, Yu Koung ^c   Jung, Woon Won ^a   Seo, Jong Bok ^d   Nam, Myung Hee ^d   Choi, Inho ^e   Chun, Taehoon ^a  

^a Korea University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d Korea Basic Science Institute (KBSI)   (South Korea)

^e Yeungnam University   (South Korea)

Author keywords

Cervical cancer; Dendritic cell; Human papilloma virus 16; Oncogenesis; T cell activation

Indexed keywords

CERVICAL CANCERS; DENDRITIC CELL; HUMAN PAPILLOMA VIRUS; ONCOGENESIS; T CELL ACTIVATION;

ANTIGENS; DISEASES; MAMMALS; PROTEINS; TUMORS; VIRUSES;

CELLS;

E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; HYBRID PROTEIN; IMMUNOGLOBULIN; ONCOPROTEIN; PROTEIN E7; REPRESSOR PROTEIN;

ANIMAL; ARTICLE; CELL DIFFERENTIATION; CYTOLOGY; DENDRITIC CELL; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; TH1 CELL;

ANIMALS; CELL DIFFERENTIATION; DENDRITIC CELLS; FLOW CYTOMETRY; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOGLOBULINS; LYMPHOCYTE ACTIVATION; MICE; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; TH1 CELLS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MAMMALIA; MUS;

EID: 79952763217     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-010-0489-0     Document Type: Article

References (23)

1. Astbury K, Turner MJ (2009) Human papillomavirus vaccination in the prevention of cervical neoplasia. Int J Gynecol Cancer 19: 1610-1613.
2. Chenais F, Virella G, Patrick CC, Fudenberg HH (1977) Isolation of soluble immune complexes by affinity chromatography using staphylococcal protein A-sepharose as substrate. J Immunol Meth 18: 183-192.
3. De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, de Cock KA, Ooms ME, Ressing ME, Toebes M, Franken KL, Drijfhout JW, Ottenhoff TH, Offringa R, Melief CJ (1998) Immunization with HPV16 oncoprotein-loaded dendritic cells as well as adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 58: 724-731.
4. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR (2001) Safety and immunogenicity trial in adult volunteers of a human papillomarvirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93: 284-292.
5. Hudson JB, Bedell MA, McCance DJ, Laiminis LA (1990) Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 64: 519-526.
6. Jin XW, Cash J, Kennedy AW (1999) Human papillomavirus typing and the reduction of cervical cancer risk. Cleve Clin J Med 66: 533-539.
7. Karanam B, Jagu S, Huh WK, Roden RB (2009) Devloping vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol 87: 287-299.
8. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. New Eng J Med 361: 1838-1847.
9. Kim SS, Byun HJ, Kim SH, Lee HH, Lee SJ, Kim SJ, Park CG, Chun T (2010) Soluble pig lymphocyte activation gene-3 (LAG-3; CD223) inhibits human-to-pig xenogeneic mixed lymphocyte reaction. Biotechnol Lett 32: 203-208.
10. Li J, Sun Y, Garen A (2002) Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model. Proc Natl Acad Sci USA 99: 16232-16236.
11. Ling M, Kanayama M, Roden R, Wu TC (2000) Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers. J Biomed Sci 7: 341-356.
12. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P (2004) Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101: 14567-14571.
13. + T lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res 59: 1184-1187.
14. Orth G, Favre M (1985) Human papillomaviruses. Biochemical and biologic properties. Clin Dermatol 3: 27-42.
15. Ory DS, Neugeboren BA, Mulligan RC (1996) A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA 93: 11400-11406.
16. Robson NC, Hoves S, Maraskovsky E, Schnurr M (2010) Presentation of tumor antigens by dendritic cells and challenges faced. Curr Opin Immunol 22: 137-144.
17. Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S, Cannon MJ (2009) A novel CD4 T cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7 pulsed dendritic cells. Cancer Immunol Immunother 58: 301-308.
18. Syrjänen SM, Syrjänen KJ (1999) New concepts on the role of human papillomavirus in cell cycle regulation. Ann Med 31: 175-187.
19. Takeuchi O, Akira S (2009) Innate immunity to virus infection. Immunol Rev 227: 75-86.
20. van der Burg SH, Kwappenberg KM, O'Neill T, Brandt RM, Melief CJ, Hickling JK, Offringa R (2001) Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 19: 3652-3660.
21. Yan J, Harris K, Khan AS, Draghia-Akli R, Sewell D, Weiner DB (2008) Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine 26: 5210-5215.
22. Yan J, Reichenbach DK, Corbitt N, Hokey DA, Ramanathan MP, Mckinney KA, Weiner DB, Sewell D (2009) Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine 27: 431-440.
23. zur Hausen H (1999) Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92: 690-698.